Advertisement
Advertisement
HRTX
Heron Therapeutics, Inc.
0.49
USDSponsored
-0.01
-1.64%
Aug 07, 15:59 UTC -4
Closed
After-Market
0.49
0.00
-0.57%
HRTX Earnings Reports
Positive Surprise Ratio
HRTX beat 21 of 41 last estimates.
51%
Next Report
Tomorrow BMO
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$43.04M
/$0.01
Implied change from Q1 26 (Revenue/ EPS)
+24.01%
/-125.00%
Implied change from Q2 25 (Revenue/ EPS)
+15.71%
/-150.00%
Heron Therapeutics, Inc. earnings per share and revenue
On May 11, 2026, HRTX reported earnings of -0.04 USD per share (EPS) for Q1 26, missing the estimate of -0.01 USD, resulting in a -161.44% surprise. Revenue reached 34.71 million, compared to an expected 39.12 million, with a -11.26% difference. The market reacted with a -21.05% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of 0.01 USD, with revenue projected to reach 43.04 million USD, implying an decrease of -125.00% EPS, and increase of 24.01% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Ardelyx, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-18.85%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.74
Actual
$1.92
Surprise
+9.75%
Cronos Group Inc. Common Share
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.00
Actual
$0.03
Surprise
0.00%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.36
Actual
$0.31
Surprise
-14.62%
Relmada Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.11
Surprise
+45.95%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.35
Actual
-$0.71
Surprise
-98.88%
Avita Medical, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.25
Surprise
+14.50%
electroCore, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.33
Surprise
+23.40%
Definium Therapeutics, Inc. Common Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.55
Actual
-$1.44
Surprise
-158.25%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
FAQ
What were Heron Therapeutics, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Heron Therapeutics, Inc. reported EPS of -$0.04, missing estimates by -161.44%, and revenue of $34.71M, -11.26% below expectations.
How did the market react to Heron Therapeutics, Inc.'s Q1 2026 earnings?
The stock price moved down -21.05%, changed from $1.21 before the earnings release to $0.96 the day after.
When is Heron Therapeutics, Inc. expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Heron Therapeutics, Inc.'s next earnings report?
Based on --
analysts, Heron Therapeutics, Inc. is expected to report EPS of $0.01 and revenue of $43.04M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement